BANK OF MONTREAL /CAN/ - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF MONTREAL /CAN/ ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$9,806
+25.2%
13,5070.0%0.00%
Q2 2023$7,835
-89.9%
13,507
-60.7%
0.00%
Q4 2022$77,595
-53.8%
34,334
-32.1%
0.00%
Q3 2022$168,000
-85.6%
50,583
-82.1%
0.00%
-100.0%
Q2 2022$1,167,000
+203.9%
283,269
+311.4%
0.00%
Q1 2022$384,000
-63.6%
68,860
-7.6%
0.00%
-100.0%
Q4 2021$1,054,000
+66.8%
74,543
+121.9%
0.00%
Q3 2021$632,000
+1.0%
33,591
-4.7%
0.00%
Q2 2021$626,000
+25.5%
35,262
+35.9%
0.00%
Q1 2021$499,000
+55.9%
25,956
+51.9%
0.00%
Q4 2020$320,000
+27.5%
17,093
+16.8%
0.00%
Q3 2020$251,000
-30.9%
14,634
-1.5%
0.00%
Q2 2020$363,000
+190.4%
14,860
+102.7%
0.00%
Q1 2020$125,000
-94.5%
7,331
-93.1%
0.00%
-100.0%
Q4 2019$2,281,000
-16.9%
105,643
-29.9%
0.00%0.0%
Q3 2019$2,746,000
-56.6%
150,746
-15.2%
0.00%
-60.0%
Q2 2019$6,323,000
+18.7%
177,727
+12.1%
0.01%0.0%
Q1 2019$5,327,000
-26.5%
158,543
-28.1%
0.01%
-28.6%
Q4 2018$7,247,000
-49.6%
220,539
-6.5%
0.01%
-36.4%
Q3 2018$14,376,000
+114.2%
235,825
+71.5%
0.01%
+83.3%
Q2 2018$6,713,000
-39.7%
137,491
+31.3%
0.01%
-40.0%
Q1 2018$11,129,000
+2470.2%
104,730
+1344.2%
0.01%
Q4 2017$433,000
+127.9%
7,252
-8.4%
0.00%
Q3 2017$190,000
+31.0%
7,914
+7.0%
0.00%
Q2 2017$145,000
-24.5%
7,395
-9.8%
0.00%
Q1 2017$192,000
+131.3%
8,195
+21.8%
0.00%
Q4 2016$83,000
-24.5%
6,731
+5.3%
0.00%
Q3 2016$110,000
+25.0%
6,395
+3.4%
0.00%
Q2 2016$88,000
-15.4%
6,187
-18.4%
0.00%
Q1 2016$104,000
-8.0%
7,581
+12.9%
0.00%
Q4 2015$113,000
+156.8%
6,712
+66.8%
0.00%
Q3 2015$44,000
-77.1%
4,024
-76.9%
0.00%
Q1 2015$192,000
-35.6%
17,425
-9.4%
0.00%
Q4 2014$298,000
+626.8%
19,230
+500.9%
0.00%
Q2 2014$41,000
-88.3%
3,200
-90.4%
0.00%
-100.0%
Q3 2013$350,00033,5000.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q2 2021
NameSharesValueWeighting ↓
Cormorant Asset Management, LP 1,828,400$89,281,0006.61%
Cormorant Asset Management, LP 1,500,000$73,245,0005.42%
Camber Capital Management LP 2,000,000$97,660,0003.76%
Rhenman & Partners Asset Management AB 617,652$30,160,0003.09%
BRIDGER MANAGEMENT, LLC 1,134,414$55,393,0003.00%
First Light Asset Management, LLC 374,251$18,275,0002.84%
Gs Investments, Inc. 54,000$2,636,820,0001.97%
SABBY MANAGEMENT, LLC 241,922$11,813,0001.82%
QUANTRES ASSET MANAGEMENT Ltd 50,000$2,441,0001.41%
Tibra Equities Europe Ltd 173,183$8,457,0001.27%
View complete list of NEKTAR THERAPEUTICS shareholders